This Week’s CGT News: New FDA Genome Editing Guidance  - Summary - MDSpire

This Week’s CGT News: New FDA Genome Editing Guidance 

Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T

  • April 20, 2026

  • 6 min

Share

Objective:

To summarize recent developments in genome editing safety guidelines and CAR-T therapy advancements.

Approach:
    Key Findings:
    • FDA guidance emphasizes safety assessments for genome-edited therapies using NGS.
    • Cema-cel achieved 58.3% MRD negativity in lymphoma patients, with no serious adverse events reported.
    • Long-term follow-up for CAR-T therapy may be reduced to five years based on safety data.
    • New CRISPR systems can distinguish between tumor and healthy DNA using methylation patterns.
    • CRISPR activation screening revealed pathways that enhance T-cell killing of cancer cells.
    • iPSC-derived NK cells showed potential for targeting lung cancer.
    Interpretation:

    The advancements in genome editing safety and CAR-T therapies indicate a significant shift towards more effective and safer cancer treatments, with ongoing research enhancing the precision of these technologies.

    Limitations:
    • Draft guidance from the FDA is still subject to change and may not reflect final regulatory standards.
    • Interim results from clinical trials may not fully represent long-term efficacy and safety.
    Conclusion:

    The developments in genome editing and CAR-T therapies highlight the progress in cancer treatment strategies, with a focus on safety, efficacy, and innovative technologies.

Original Source(s)

This Week’s CGT News: New FDA Genome Editing Guidance 

  • April 20, 2026

Related Content

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates

  • July 2, 2026

  • 1 min
Surviving CGT's Funding Winter

In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

  • by

  • July 7, 2026

  • 8 min